Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Results 1 - 20 of 226 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Defshark82 (66.92) Submitted: 12/31/2014 11:44:21 AM : Outperform Start Price: $59.78 BMY Score: +5.68

Tracking JPM top pick

Recs

0
Member Avatar foolmelgoner (80.38) Submitted: 12/15/2014 8:49:32 PM : Outperform Start Price: $57.94 BMY Score: +4.34

Solid pipeline, good management

Recs

0
Member Avatar AnsgarJohn (98.15) Submitted: 11/16/2014 8:54:06 AM : Underperform Start Price: $57.37 BMY Score: -8.08

Bristol-Myers a favorite of Jima Cramer and Fools, but seems to be getting ahead of itself. PE almost 40, not much growth. End ASAP http://www.gurufocus.com/stock/BMY&summary

Recs

0
Member Avatar mrgekko (50.10) Submitted: 11/7/2014 4:56:31 AM : Outperform Start Price: $57.90 BMY Score: +6.75

some great phase 3 drugs and in the right areas

Recs

0
Member Avatar JeffRossMD (< 20) Submitted: 10/30/2014 12:44:24 PM : Outperform Start Price: $57.90 BMY Score: +4.59

The biotech space is just heating up as new technologies are revolutionizing cancer and chronic disease processes.

Recs

0
Member Avatar mikeayu (< 20) Submitted: 10/14/2014 7:06:01 PM : Outperform Start Price: $48.06 BMY Score: +19.00

Huge upside from cancel drugs.

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 10/1/2014 2:23:35 PM : Outperform Start Price: $50.20 BMY Score: +15.31

Div. (Yield) $1.44 (2.8%)

Recs

0
Member Avatar Herbstmd (50.58) Submitted: 8/22/2014 11:55:42 AM : Outperform Start Price: $49.37 BMY Score: +23.41

Developing great new cancer drugs called PD1, which may revolutionize cancer therapy.

Recs

0
Member Avatar Kenji94 (58.76) Submitted: 8/19/2014 1:29:19 AM : Underperform Start Price: $49.50 BMY Score: -22.33

There is a disconnection between price and fundamentals. I would like to own the company, but not at this price.

Recs

0
Member Avatar hydn (< 20) Submitted: 5/16/2014 10:28:57 AM : Outperform Start Price: $47.78 BMY Score: +20.85

Solid demand for ever improving products.

Recs

0
Member Avatar Johnybe (68.28) Submitted: 5/14/2014 9:46:28 PM : Outperform Start Price: $48.50 BMY Score: +19.89

strong player in this sector

Recs

0
Member Avatar DRGRNR (< 20) Submitted: 4/15/2014 7:52:17 PM : Outperform Start Price: $47.43 BMY Score: +20.91

I've owned BMY for 30 years, always a strong performer.

Recs

0
Member Avatar bassnman45 (41.30) Submitted: 1/2/2014 9:30:25 PM : Outperform Start Price: $20.73 BMY Score: +132.63

buy, hold long term and monitor

Recs

1
Member Avatar johnclanaro (< 20) Submitted: 10/28/2013 3:54:27 PM : Outperform Start Price: $50.37 BMY Score: +7.42

recent upgrade. good pipeline.

Recs

1
Member Avatar gilmomp1 (56.25) Submitted: 10/16/2013 9:38:21 PM : Outperform Start Price: $46.94 BMY Score: +13.18

I bought 100 shares of this company pre 1995 and now own 188 shares by reinvesting my dividends. Now that I'm nearing retirement that dividend looks pretty good!

Recs

1
Member Avatar nancytroi (< 20) Submitted: 10/2/2013 11:43:34 AM : Outperform Start Price: $45.09 BMY Score: +16.68

Continues finding new drugs to fight cancers

Recs

0
Member Avatar lg7691 (23.63) Submitted: 7/21/2013 1:34:10 PM : Outperform Start Price: $42.45 BMY Score: +25.87

7/21/13 44.19 drug stock

Recs

2
Member Avatar usubanas (99.73) Submitted: 5/15/2013 2:35:44 AM : Outperform Start Price: $40.18 BMY Score: +30.92

I'm buying this tomorrow because of PD-1

Recs

0
Member Avatar DonkeyJunk (31.68) Submitted: 5/5/2013 10:39:09 PM : Underperform Start Price: $38.18 BMY Score: -36.39

Stock with a PE of almost 50 in an on-average overvalued market due for a significant pullback. With a company this size, the increase in revenue would have to be astronomical to justify the price.

Recs

0
Member Avatar mfwatcher (< 20) Submitted: 2/9/2013 10:45:25 AM : Outperform Start Price: $34.77 BMY Score: +44.24

Product pipeline has it positioned to outperform its peers during the recovery period.

Featured Broker Partners


Advertisement